10 December @ 8:00 am – 8:00 pm Europe/London
For more than two decades, Genesis has united key opinion leaders, R&D innovators, investors, and industry stakeholders to discuss trends, initiate partnerships, and elevate breakthrough science.
Join our Director General, Dr Claire Skentelbery in London for Genesis 2026 on the 10th of December where she will be speaking in Keynote Panel 1: How Can You Scale a UK Biotech Without Selling Out to a Richer International Counterpart?
The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.
Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.
Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.
Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.
Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.
Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.
